Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828

Detalles Bibliográficos
Autores principales: Kohsaka, Shun, Okami, Suguru, Morita, Naru, Yajima, Toshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095320/
https://www.ncbi.nlm.nih.gov/pubmed/37048834
http://dx.doi.org/10.3390/jcm12072578
_version_ 1785024055770873856
author Kohsaka, Shun
Okami, Suguru
Morita, Naru
Yajima, Toshitaka
author_facet Kohsaka, Shun
Okami, Suguru
Morita, Naru
Yajima, Toshitaka
author_sort Kohsaka, Shun
collection PubMed
description
format Online
Article
Text
id pubmed-10095320
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100953202023-04-13 Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828 Kohsaka, Shun Okami, Suguru Morita, Naru Yajima, Toshitaka J Clin Med Correction MDPI 2023-03-29 /pmc/articles/PMC10095320/ /pubmed/37048834 http://dx.doi.org/10.3390/jcm12072578 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Correction
Kohsaka, Shun
Okami, Suguru
Morita, Naru
Yajima, Toshitaka
Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
title Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
title_full Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
title_fullStr Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
title_full_unstemmed Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
title_short Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
title_sort correction: kohsaka et al. risk–benefit balance of renin–angiotensin–aldosterone inhibitor cessation in heart failure patients with hyperkalemia. j. clin. med. 2022, 11, 5828
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095320/
https://www.ncbi.nlm.nih.gov/pubmed/37048834
http://dx.doi.org/10.3390/jcm12072578
work_keys_str_mv AT kohsakashun correctionkohsakaetalriskbenefitbalanceofreninangiotensinaldosteroneinhibitorcessationinheartfailurepatientswithhyperkalemiajclinmed2022115828
AT okamisuguru correctionkohsakaetalriskbenefitbalanceofreninangiotensinaldosteroneinhibitorcessationinheartfailurepatientswithhyperkalemiajclinmed2022115828
AT moritanaru correctionkohsakaetalriskbenefitbalanceofreninangiotensinaldosteroneinhibitorcessationinheartfailurepatientswithhyperkalemiajclinmed2022115828
AT yajimatoshitaka correctionkohsakaetalriskbenefitbalanceofreninangiotensinaldosteroneinhibitorcessationinheartfailurepatientswithhyperkalemiajclinmed2022115828

Ejemplares similares